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ABSTRACT
The 7SK small nuclear ribonucleoprotein (snRNP) sequesters and inactivates the positive transcription
elongation factor b (P-TEFb), an essential eukaryotic
mRNA transcription factor. The human La-related
protein group 7 (hLARP7) is a constitutive component of the 7SK snRNP and localizes to the 3 terminus of the 7SK long noncoding RNA. hLARP7, and
in particular its C-terminal domain (CTD), is essential
for 7SK RNA stability and assembly with P-TEFb. The
hLARP7 N-terminal La module binds and protects the
3 end from degradation, but the structural and functional role of its CTD is unclear. We report the solution
NMR structure of the hLARP7 CTD and show that this
domain contains an xRRM, a class of atypical RRM
first identified in the Tetrahymena thermophila telomerase LARP7 protein p65. The xRRM binds the 3 end
of 7SK RNA at the top of stem-loop 4 (SL4) and interacts with both unpaired and base-paired nucleotides.
This study confirms that the xRRM is general to the
LARP7 family of proteins and defines the binding site
for hLARP7 on the 7SK RNA, providing insight into
function.
INTRODUCTION
The RNA 7SK is one of the first discovered and among
the most abundant long noncoding RNAs (lncRNAs), with
over 100 000 copies per cell in HeLa cells (1). 7SK, an
RNA Polymerase III (RNAPIII) transcript, functions as
a scaffold that dynamically binds several proteins, forming a small nuclear ribonucleoprotein (snRNP) complex
whose primary known function is to sequester and inactivate the positive transcription elongation factor b (PTEFb), an essential eukaryotic transcription activator (2,3).
P-TEFb, a heterodimer of the kinase cyclin dependent kinase 9 (CDK9) and cofactor Cyclin T1, phosphorylates
negative elongation factors (NEFs) and Ser2 in YSPTSPS
repeats in the RNAPII C-terminal tail, which transitions
RNAPII initiation complexes from stalled to productive
* To

elongation complexes (4). In this way, the 7SK snRNP is
an essential regulator of messenger RNA transcription. Improper regulation of P-TEFb can give rise to many human
diseases, e.g. cardiac hypertrophy (5), leukemia (6–8), lymphoma (9), cervical cancer (10), and gastric cancer (11,12).
Furthermore, in the HIV replication cycle, P-TEFb is hijacked from the 7SK snRNP by the transactivator of transcription (TAT) protein and recruited to the HIV 5 UTR
transactivation response (TAR) element (13–17) to facilitate HIV replication, making P-TEFb an essential host cofactor for replication of the HIV genome (18,19).
The 7SK secondary structure determined by early chemical footprinting studies showed that 7SK consists of four
stem-loops (Figure 1A) (20), although more recent sequence alignment of 79 7SK sequences including both vertebrates and invertebrate species suggests that up to eight
stem-loops can form (21). In both secondary structure models, stem loop 4 (SL4) has the same overall secondary structure, consisting of a hairpin containing a two-pyrimidine
nucleotide bulge, a five-nucleotide apical loop, and a singlestranded UUU-3 OH. SL4 is highly conserved in both sequence and secondary structure, with loop residue G312
100% conserved (22). The solution NMR structure of a
human 7SK SL4 construct bound to arginine showed that
bulge residue C320 forms an unusual base triple with the
G303-C323 base pair (23), similar to the base triple observed in HIV TAR (24–26).
Two proteins, methylphosphate capping enzyme
(MePCE) and the La-related group 7 protein (LARP7),
are constitutively bound to 7SK in vivo (27,28). In addition
to this ‘core’ ternary complex, the kinase inhibitor hexamethylene bis-acetamide inducible protein 1, HEXIM1
(and less frequently HEXIM2) (29–31), and P-TEFb
bind to form the minimal ‘active’ 7SK snRNP capable of
sequestering and inactivating the kinase activity of P-TEFb
(2,3). Several other proteins dynamically associate with
7SK to form different 7SK snRNP complexes, including
CTIP2 (32); hnRNPs A, Q, and R (33); HMGA1 (34–38);
KAP1 (39); PPM1G (40) and DDX21 helicase (41). While
HEXIM1 is required to sequester P-TEFb in the 7SK
snRNP complex, the remainder of these proteins appears
to be involved in P-TEFb recruitment to RNAPII and/or
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Figure 1. LARP7 family protein domain structure and homology. (A) Cartoon schematic of 7SK RNA with SL4 construct used for studies shown
inset, with residues that deviate from wild-type shown in gray. (B) Domain
structure of LARP7 family proteins human LARP7 (a component of 7SK
RNP), Tetrahymena thermophila p65 and Euplotes p43 (telomerase holoenzyme components), and human genuine La protein. All contain a La module (La+RRM1) followed by a second RRM2 domain. (C) Schematic of
the main RRM constructs used in this study. (D) Sequence alignment
of human (hLARP7), mouse (mLARP7), and Drosophila melanogaster
(dLARP7) LARP7 putative RRM2s, human genuine La (hLa), Euplotes
p43, and Tetrahymena p65. Residues in red denote highly conserved equivalent residues. The RNP3 sequence and conserved Arg in ␤3, first identified
in p65, are boxed in blue. Secondary structure elements (arrow, ␤-strand;
solid cylinder, ␣-helix; open cylinder, predicted ␣-helix) at top and bottom
denote those experimentally determined for hLARP7 and p65 xRRM2,
respectively.

release from the 7SK snRNP. In vitro, LARP7 remains
bound even under high salt (800 mM NaCl) conditions
where HEXIM1, Cyclin T1 and CDK9 dissociate (27).
LARP7’s known function is to protect the 7SK RNA from
3 end degradation, and it also appears to be required for
P-TEFb association to the 7SK snRNP (27,42).
Human LARP7 (hLARP7), also known as PIP7S (43)
and HDCMA18p (44), is a member of the genuine La
and La-related protein (LARP) superfamily (44,45) and
contains two structured domains: an N-terminal La module, comprised of a Lupus antigen motif (LaM) and a
RNA recognition motif (RRM) that together recognize the
UUU-3 OH of RNAPIII transcripts, and a C-terminal domain (CTD) that is predicted to contain a second RRM
(Figure 1B) (27,42). While the N-terminal La module binds
the 7SK UUU-3 OH terminus and is necessary in preventing 7SK RNA degradation (27,43,46), the role of the
CTD remains speculative. Deletion of the hLARP7 CTD
resulted in loss of the ability of hLARP7 to discriminate
7SK against other RNAPIII transcripts with UUU-3 OH
ends (43). hLARP7 has been identified as a tumor suppressor and is downregulated in gastric cancer (11) and metastasized cervical cancer tumors (10). Frameshift mutations resulting in premature truncation of hLARP7 are correlated
with human gastric cancer (10–12) and can cause a form of
primordial dwarfism (47–49). An hLARP7 construct lacking the CTD failed to sequester P-TEFb in the 7SK snRNP
complex (43,50), suggesting that this domain plays an important role in the stable association of P-TEFb to the 7SK
snRNP.

The predicted LARP7 RRM2 sequence is highly conserved from Drosophila melanogaster to humans and shares
sequence homology with the RRM2 of the other known
LARP7 family proteins p65, found in Tetrahymena thermophila, and its homolog p43 in Euplotes, as well as with
genuine La protein (Figure 1D). p65 is an essential protein
component of the Tetrahymena telomerase holoenzyme and
is required for telomerase assembly, activity, and processivity in vivo (51). Structural studies revealed the p65 CTD
contained a novel class of atypical RRM, named xRRM
(52,53). Unusual features of the xRRM include the absence
of conserved RNP1 and RNP2 aromatic sequences on the
␤3 and ␤1 strands, respectively, typically involved in nucleotide recognition; the presence of an additional helix ␣3
that lies across the ␤-sheet surface, where single-stranded
nucleotides usually bind; and a C-terminal tail required for
RNA binding that is disordered in the free xRRM but forms
an ␣3 extension (␣3x) on binding RNA. On binding p65,
Tetrahymena telomerase RNA stem 4 (S4) undergoes a large
conformational change including inducing a ∼105◦ bend.
Based on sequence and predicted structural homology it
was proposed that the xRRM might be common to other
LARP7 and La family proteins (52,53). To investigate this
possibility and determine the structural basis for the role
of the hLARP7 CTD in 7SK snRNP assembly, we solved
the solution NMR structure of the hLARP7 RRM2, identified the domain boundaries for 7SK RNA binding, and
mapped the protein and RNA binding interface. We find
that the hLARP7 RRM2 is an xRRM that binds to the 7SK
SL4 upper stem and apical loop residues, thereby recognizing both unpaired and base paired nucleotides in a manner similar to p65 xRRM but at a hairpin rather than an
internal bulge. These findings show that the xRRM is not
unique to Tetrahymena p65 but rather appears to be common to LARP7 family proteins and establish the binding
site of hLARP7 xRRM on 7SK SL4 RNA, providing insight into function.
MATERIALS AND METHODS
Sample preparation
hLARP7 RRM2 constructs (Figure 1C) were cloned into
the pet30 Xa/LIC vector with a His6 affinity tag, modified using site-directed mutagenesis to remove the Xa sequence between the His tag and RRM2, and expressed in
Escherichia coli BL21 (DE3) cells with a final concentration of 1 mM IPTG, grown at 18◦ C for 18–20 h. Cells were
pelleted, resuspended in buffer R (20 mM Tris pH 8.0, 500
mM NaCl, 15 mM imidazole, 1 mM TCEP, 0.002% NaN3 ),
and lysed via sonication. Cells were centrifuged to separate
the soluble fraction that was subsequently run on a 5 mL
HisTrap HP nickel affinity column (GE Healthsciences).
The column was washed with buffer R and eluted with
buffer E (20 mM Tris pH 8.0, 500 mM NaCl, 200 mM imidazole, 1 mM TCEP). The elution fraction was concentrated and further purified on an S75 column attached to
AKTA FPLC (GE Healthsciences). Fractions containing
pure protein were pooled, buffer exchanged into protein
NMR buffer (20 mM NaPO4 pH 6.1, 100 mM NaCl, 1 mM
TCEP, 0.002% NaN3 ) using a 3 kDa Amicon (EMD Millipore), and concentrated to 0.8–1 mM for NMR studies. Un-
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labeled protein was purified from cells grown in LB media
(Fisher) and uniformly 15 N- and/or 13 C- labeled proteins
were purified from cells grown in M9 minimal media with
15
N ammonium chloride and/or 13 C D-glucose (Cambridge
Isotope Labs) as the sole nitrogen and/or carbon source, respectively.
The 7SK SL4 RNA hairpin (called SL4, residues 300–
326), modified by substituting the terminal G–U base pair
with a G–C base pair and adding a terminal G–C base pair
(Figure 1A) was in vitro transcribed using T7 RNAP (P266L
mutant) (54) and chemically synthesized DNA templates
(Integrated DNA Technologies) following established protocols (55). Briefly, the transcription reaction (40 mM Tris
pH 8, 25 mM MgCl2 , 1 mM spermidine, 0.01% Triton X,
2.5 mM DTT, 2 mM each rATP, rCTP, rUTP, rGTP, 0.5
M DNA template) was incubated at 37◦ C for 4–6 h. Transcribed RNA was purified by 15–20% denaturing polyacrylamide gel electrophoresis (PAGE), the band containing
RNA was visualized by UV shadowing and excised from the
gel, and RNA was electroeluted from the gel pieces using an
Elutrap device (GE Waters). RNA was further purified by
ion-exchange chromatography using a DEAE column (GE
Healthcare) and eluted into 10 mM sodium phosphate pH
7.6, 1 mM EDTA, 1.5 M KCl. RNA was diluted to <100
M in ddH2 O and annealed by heating to 95◦ C for 3 min,
followed by incubation on ice for 1 h. RNA was then buffer
exchanged into appropriate buffer using a 3 kDa Amicon
and concentrated to 0.4–1 mM. For NMR studies the RNA
was exchanged into protein-RNA complex NMR buffer (20
mM sodium phosphate pH 6.05, 50 mM KCl, 1 mM TCEP).
The xRRM-RNA complex was prepared using a minimal
xRRM construct called RRM2-556 (residues 445–556), in
which a Tobacco etch virus (TEV) protease site was placed
(ENLYQ) between the His6 tag and residue S445. The protein was expressed and purified as described above. After
affinity purification on the NTA column, RRM2-556 was
dialyzed (20 mM Tris HCl pH 7.5, 50 mM NaCl, 1 mM
TCEP) for 1–2 h at ambient temperature in the presence
of TEV protease (recombinantly expressed and purified in
house) to cleave the His6 tag. RRM2-556 was purified on
the HisTrap HP column a second time to separate cleaved
from uncleaved protein, and the cleaved protein was further
purified on an S75 column. Purified RRM2-556 protein was
added to a SL4 RNA hairpin at a 1:1.2 ratio, respectively,
under dilute conditions (∼25 M) in protein-RNA complex
NMR buffer and concentrated to ∼500 l using a 3 kDa
Amicon to a final concentration of ∼0.8 mM.
NMR spectroscopy
NMR protein samples were concentrated to 0.5–1.0 mM
in protein NMR buffer in either 90% H2 O/10% D2 O or
lyophilized and resuspended in 99.996% D2 O. NMR experiments were performed at 298 K on AVANCE 800
MHz Bruker spectrometer equipped with HCN cryoprobe.
Backbone (N, H, C, C␣, C␤, H␣, H␤) and side-chain
(C␦, C␥ , C⑀, H␦, H␥ , H⑀) assignments were obtained
using standard triple resonance assignment experiments
(56,57). Briefly, 3D CBCACONH, HNCACB, HNCA, HBHACONH, HNCO and HNCACO experiments from the
Bruker experimental suite were acquired and analyzed to

assign backbone resonances. The CCCONH experiment
was acquired to assign all carbon atoms in a given residue.
Once backbone assignments were completed the sample
was lyophilized and re-dissolved into 99.996% D2 O for
side-chain assignments. 3D TOCSY and HCCH-COSY experiments were acquired to assign side-chain resonances.
15
N- and 13 C-edited 3D NOESY experiments were acquired
on samples in 90% H2 O/10% D2 O or 99.996% D2 O respectively with a mixing time of 120 ms to obtain nuclear
Overhauser effect crosspeaks (NOEs) for structure determination. NMR data was collected using XwinNMR 3.5
(Bruker), processed using NMRPipe (58), and analyzed using Sparky 3.110 (59). Hydrogen–deuterium exchange experiments were acquired to determine residues protected
from solvent through hydrogen bonding as follows. A 500
l sample of 0.5 mM protein in protein NMR buffer was
lyophilized for 18 h. The sample was resuspended in the
equivalent volume 99.996% D2 O and quickly transferred
to an NMR tube. 1.5 min SOFAST HMQC 1 H–15 N experiments (60) were run successively for 24 h to observe
hydrogen-to-deuterium exchange of backbone amide protons. One-bond 1 H–15 N residual dipolar couplings (RDCs)
were measured from analysis of 2D 1 H–15 N HSQC-IPAP
experiments (61) in the absence and presence of 10 mg/ml
Pf1 phage (ASLA Biotech, Ltd), with an observed deuterium splitting of ∼3 Hz. A total of 51 RDCs were used
to refine the hLARP7 RRM2 structure (Table 1). The
weighted average chemical
shifts were calculated using the

following equation i 2 + x j 2 , where i is the change
in chemical shift in the 1 H dimension, j is the change in
chemical shift in the second dimension (1 H, 15 N or 13 C),
and x is a coefficient that scales the chemical shift changes
of the second dimension according to the ratio between the
gyromagnetic ratios γ j /γ i , where x = 1 for 1 H, 0.1 for 15 N
and 0.25 for 13 C (57).
NMR structure calculation
The hLARP7 RRM2-561 structure was calculated in a
semi-automated iterative manner using CYANA 2.1 (62).
Intra- and inter-residue NOEs were manually picked from
the 3D NOESY experiments. Dihedral angle restraints
were generated using the software Talos+ (63). Hydrogen
bond restraints were determined by hydrogen-deuterium exchange experiments and observation of NOE crosspeaks
characteristic to ␣-helices and ␤-sheets. NOE peaklists, dihedral angle restraints, hydrogen bond restraints, and chemical shift assignments were used as input for CYANA 2.1 to
generate 100 starting conformers. After each round of calculations NOESY spectra were re-analyzed to update the
NOE peak list and add new NOEs consistent with the preliminary model. After multiple iterations, the preliminary
structure was refined in XPLOR with additional RDC restraints. The 20 lowest energy structures out of 200 models
were selected for the final ensemble.
Electrophoretic mobility shift assay (EMSA)
SL4 RNA and hLARP7 RRM2 samples were prepared separately in protein-RNA complex NMR buffer at 50 M
concentrations. RNA and protein were added together at
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Table 1. Restraints and structure statistics for solution NMR structure of
hLARP7 xRRM (residues 445 to 561)
Distance and dihedral angle restraints
Total NOE restraints
1306
Intraresidue
327
Sequential
407
Medium (i+2 to i+4)
189
Long range (>i+4)
383
Hydrogen bond restraints
88
RDC restraints
51
Dihedral angle restraints
135
Structure Statistics (20 lowest energy structures)
No. NOE violations >0.2 Å
0
No. Dihedral violations >5◦
0
No. RDC violations >2 Hz
0
RMSD of RDC (Hz)
2
RMSD from ideal covalent geometry
Bond lengths (Å)
0.00108 ± 0.00005
Bond angles (◦ )
0.313 ± 0.003
Impropers (◦ )
0.207 ± 0.005
RMSD from mean structure
Residues 20–24, 32–42, 46–50, 56–61, 64–74, 84–88, 91–104
Backbone (Å)
0.37
Heavy atoms (Å)
0.80
Ramachandran statistics
Most favored regions
88.2%
Additional allowed regions
10.2%
Generously allowed regions
1.6%
Disallowed regions
0.0%

to 7SK SL4, we made a series of protein constructs with serial C-terminal truncations (Figure 1C and Table 2). Previous chemical footprinting studies on hLARP7 La module
and CTD domains indicated that the La module but not
the CTD binds to the UUU-3 OH (66). For binding studies, we used an RNA construct of SL4 (residues 300–326)
modified by substituting the terminal G–U base pair with
a G–C base pair and adding an additional G–C base pair
at the end to facilitate transcription by T7 RNAP (Figure
1A). To verify specific binding of this SL4 construct to the
hLARP7 CTD, we measured 1 H–15 N HSQC NMR spectra of uniformly 15 N-labeled RRM2-582, consisting of a Nterminal His6 affinity tag and residues 445–582, in the absence and presence of SL4 (Figure 2A). On titration of SL4,
many peaks in the RRM2-582 construct initially broadened and/or disappeared and subsequently new peaks appeared as the concentration of SL4 increased, characteristic of intermediate-to-slow chemical exchange (Supplemen-
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tary Figure S1). No further chemical shift changes in the
H–15 N HSQC spectra were observed above a ratio of 1:1.2
of RRM2-582:SL4. Using isothermal titration calorimetry
(ITC) measurements we found that RRM2-582 bound SL4
RNA with high affinity (97 ± 13 nM) with a one-to-one
stoichiometry (Figure 2B and Table 2) The one-to-one stoichiometry was also confirmed by electrophoretic mobility shift assay (EMSA) (Supplementary Figure S1). Deletion of up to 31 C-terminal amino acids (aa, RRM2-561,
RRM2-556 and RRM2-551), had a minimal effect on binding with a 1.3, 1.5-fold and 2-fold reduction, respectively
(Figure 2, Supplementary Figure S2, and Table 2). Truncation of another 5 aa (RRM2-546) reduced binding 18-fold,
to 1824 ± 45 nM. Finally, deletion of another 9 aa (RRM2537) reduced binding 40-fold compared to RRM2-582 (Table 2 and Supplementary Figure S2). These experiments define the minimal hLARP7 RRM2 C-terminal boundary required for high-affinity RNA binding as residue 551.
1

Solution NMR structure of hLARP7 RRM2
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Initial NMR studies were performed on RRM2-582, which
has well dispersed peaks in the backbone amide 1 H–15 N
HSQC spectrum indicative of a folded protein (Supplementary Figure S3). Backbone resonance assignments (H, N,
C, C␣, C␤, H␣, H␤) were completed for 88% of resonances
using standard NMR experiments on a uniformly 15 N,13 Clabeled sample (Supplementary Table S1). The first eight
residues, including the His6 tag and first two residues of the
construct, were not observed in the 2D 1 H–15 N HSQC spectrum. Chemical shift indexing (CSI) using Talos+ (63) indicates that RRM2-582 residues 455–570 adopt a ␤␣␤␤␣␤␣␣
topology, consistent with an RRM having additional ␣3
and ␣4 helices at the C-terminus (Supplementary Figure
S4). In agreement with CSI, residues 455–537 had 1 H–15 N
heteronuclear NOE (hetNOE) values of ∼0.9 (Supplementary Figure S5), consistent with the RRM2 boundaries predicted by the NCBI conserved domain database. Predicted
loop regions ␤1-␣1, ␤2-␤3, and ␣2-␤4 have lower 1 H–15 N
hetNOE values. The ␣2-␤4 loop, particularly residues 517–
520, appears to be the most disordered, with a minimum of
∼0.7 for residue 518. These amide resonances also show line
broadening indicative of chemical exchange. 1 H–15 N hetNOE values decrease gradually from residues 538 (0.8), the
fourth residue from the C-terminal end of ␣3 predicted by
CSI, to terminal residue 582 (-0.1) (Supplementary Figure
S5). Interestingly, residues 559–571, predicted to form an
␣4 helix by CSI, have elevated 1 H–15 N hetNOE s of ∼0.6
compared to the C-terminal end (residues 552–582) (Supplementary Figure S5).
Due to the high degree of disorder and resonance overlap in the C-terminal residues of RRM2-582, RRM2-561
was used for structure determination. As shown above, deletion of residues beyond 551 does not significantly affect
RNA binding. 2D 1 H–15 N HSQC spectra are nearly identical between the two constructs, confirming that they have
the same global fold (Supplementary Figure S3). Backbone
and sidechain resonances were assigned by standard 3D
NMR protein assignment experiments. Small chemical shift
differences between RRM2-582 and RRM2-561 are only
observed for C-terminal residues 556–561. In RRM2-582

these residues are at the N-terminus of the putative helix ␣4 whereas in RRM2-561 these residues are at the Cterminus, explaining the difference in chemical shift. The
secondary structure determined from CSI for residues up to
559 are identical (Supplementary Figure S4). 1 H–15 N hetNOE values (Supplementary Figure S3) for RRM2-561 are
also nearly identical to RRM2-582, with the exception of
C-terminal residues 558–561, which all have values below
zero, indicating a high degree of flexibility.
A solution NMR structure of RRM2-561 was solved to
a backbone RMSD of 0.38 Å (heavy atom RMSD 0.80 Å)
for the 20 lowest energy structures (Figure 3A and Table
1). The hLARP7 RRM2 structure is an atypical RRM consisting of four ␤-sheets and three ␣-helices. The front face
of the RRM consists of an antiparallel ␤-sheet comprising
␤4 (residues 520–523), ␤1 (residues 456–460), ␤3 (residues
493–496), and ␤2 (residues 482–486) strands with helix ␣3
(residues 537–544) lying across the ␤-sheet perpendicular to
the ␤-strand axis (Figure 3A). The back side of the RRM
consists of two ␣-helices: helix ␣1 (residues 468–478) lies under ␤2 and ␤3 while helix ␣2 (residues 500–516) lies under
␤4. There are 5 structured loops: ␤1-␣1 (residues 461–467),
␣1-␤2 (residues 479–481), ␤2-␤3 (residues 487–492), ␤3␣2 (residues 497–499), ␣2-␤4 (residues 517–519), and ␤4␣3 (residues 524–536). The interface between helix ␣3 and
the ␤-sheet consists of mainly aromatic and hydrophobic
residues (H494, L524, H528, E529, Y532, W533, I536) with
a - stacking interaction between H494 and Y532 (Figure
3B). At the C-terminal end of helix ␣3 and at the interface
with the ␤2 strand, residues are predominantly charged or
aromatic (Y483, D485, R496, K535, D539, R540, K543)
(Figure 3B). The C-terminal seven residues of helix ␣3
(residues 538–544) extend past the ␤-sheet surface. Helix
␣3x, predicted to encompass residues 545–552, are disor-
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Figure 3. Solution NMR structure of hLARP7 RRM2-561. (A) (left) Ensemble of the 20 lowest energy NMR structures. Disordered residues 445–
449 and 553–561 that are outside of the xRRM boundary are not shown
in the figure. ␤ strands shown in orange, with ␣3 shown in red and putative
␣3x residues shown in gray. (right) View of lowest energy conformation rotated to show RNA binding surface and RNP3 (blue). Residues 545–561
are not shown. (B) Helix ␣3 is stabilized on the ␤-sheet by hydrophobic
(green) and aromatic (yellow) stacking interactions. Left: ␤3 residue H494
and ␣3 residue Y532 stack. Right: 180◦ rotation to show ␤-sheet and ␣3
interface on other side of xRRM. Charged residues (in purple) are located
at the putative RNA binding site in helix ␣3 past the ␤-sheet.
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− 21
− 21
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0.02
0.01
0.03
0.02
0.01
0.2

dered as are the nine C-terminal residues (residues 553–
561).
The hLARP7 RRM2 structure gives insight into the ITC
data above. Deletion of the predicted helix ␣4 and disordered C-terminal aa up to residue 551 reduced the binding
affinity only 1.3 to 2-fold (Figure 2, Supplementary Figure S2, and Table 2). However, deleting six of eight putative ␣3x residues in addition to helix ␣4 (RRM2-546) reduced binding 18-fold indicating that the putative ␣3x is important for RNA binding. Further truncation of the last 6
residues of helix ␣3 (RRM2-537), reduced binding 40-fold
compared to RRM2-582 (Table 2 and Supplementary Figure S2). These data implicate helix ␣3 and the putative ␣3x
in RNA binding, as expected for an xRRM.
Canonical RRMs characteristically bind RNA on the
␤-sheet surface with conserved RNA-recognition sequences RNP1 [(R/K)-G-(F/Y)-(G/A)-(F/Y)-(I/L/V)-X(F/Y)] and RNP2 [(I/L/V)-(F/Y)-(I/L/V)-X-N-L] on ␤3
and ␤1, respectively (53,67,68). hLARP7 RRM2 lacks both
RNP1 and RNP2: the ␤3 sequence is CHAR and the ␤1
sequence is IVKII (Figure 1D). p65 also lacks canonical
RNP1 and RNP2 sequences; rather, a conserved arginine
in ␤3 along with a proposed xRRM-specific RNP3 sequence in ␤2 [(Y/W)-X-D] interacts with single-stranded
nucleotides of its target telomerase RNA. The hLARP7
RRM2 also contains the xRRM-specific RNP3 sequence
(YVD) and conserved arginine in ␤3 (Figures 1D and 3A),
suggesting it is an xRRM.
Interaction of hLARP7 xRRM2 with 7SK SL4
To investigate the structural and dynamic properties of the
hLARP7 RRM2 in the presence of 7SK SL4 RNA and determine if residues 545–552 form ␣3x on binding RNA, we
prepared a complex of uniformly 13 C,15 N-labeled RRM2556 bound to unlabeled SL4 RNA (Figure 4A). As observed
for RRM2-582, RRM2-556 binding to SL4 occurred on
the intermediate-to-slow exchange regime, and the RRM2556:SL4 complex saturated at a 1:1.2 ratio. RRM2-556
bound to SL4 had the best quality NMR spectra compared
with longer RRM2 constructs, and complete backbone assignments were obtained for RRM2-556:SL4. 1 H–15 N hetNOEs were measured on free and SL4-bound RRM2-556
to determine if the residues of the putative helix ␣3x become
more ordered in the presence of SL4 (Figure 4B). While
1
H–15 N hetNOE values of structured regions (residues 550539) do not change significantly when SL4 is added, helix
␣3 residues 538–544 and putative helix ␣3x residues 545–
553 have significantly increased 1 H–15 N hetNOE values,
indicating an increase in order at the C-terminus (Figure
4B). The requirement for these C-terminal residues for high-
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Figure 4. Mapping the hLARP7 xRRM2 RNA binding surface. (A) 1 H–
15 N HSQC of free (black) and bound at 1:1.2 protein:RNA ratio (blue)
RRM2-556 show large CSPs on binding 7SK SL4 RNA. (B) 1 H–15 N hetNOE of free (black) and bound (blue) to SL4 RNA show similar values
for folded regions of the protein, with higher values for the putative ␣3x
helix indicating an increase in order. (C) Left: CSPs mapped onto free
RRM2-561 solution NMR structure, right: plot of backbone amide CSP of
RRM2-556 on binding 7SK SL4. Dashed line indicates the average CSP
(0.16 ppm). CSPs were binned as follows: 0.16–0.5 ppm (cyan), 0.5–0.7
ppm (blue), 0.7 ppm (dark blue).

affinity binding to SL4 RNA, coupled with the increase in
order on binding RNA, indicates that helix ␣3x forms in the
presence of SL4.
Three of the defining features of the xRRM are that (i)
it binds RNA on the ‘side’ of its ␤-sheet rather than on
the surface of the ␤-sheet, as is characteristic of canonical
RRMs, (ii) it features a disordered C-terminal tail that becomes ordered on binding RNA, forming a helix ␣3x extension and (iii) it binds both unpaired and base paired RNA
nucleotides. To investigate the RNA binding surface of the
hLARP7 RRM2 we performed chemical shift mapping experiments using the weighted average chemical shift perturbation (CSP) of unbound and bound backbone amide resonances in 1 H–15 N HSQC spectra. Significant CSPs (defined as greater than the average change of 0.16 ppm) occur primarily at ␤2, ␤3, ␣3, and the four disordered Cterminal residues after helix ␣3 (Figure 4C). Notably, conserved residues in ␤2, ␤3, and ␣3 (Y483, D485, R496, I536,
R540), which in p65 were involved in direct contacts to
Tetrahymena telomerase S4 RNA, have CSPs, suggesting
they are involved in RNA recognition. Some of the largest
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CSPs were observed for residues at the C-terminal end of
helix ␣3 (L537-D539) and the beginning of the putative ␣3x
(N545-Q546), which may also reflect in part formation of
helix ␣3x helix on binding SL4, in agreement with hetNOE
data. HetNOE and CSP data combined with the requirement for the C-terminal residues confirm that hLARP7
RRM2 is an xRRM.
SL4 requirements for recognition by hLARP7 xRRM
Muniz et al showed that many elements of the 7SK 3 stemloop SL4, including both upper and lower stems, an internal
bulge, and nucleotides G312 and U313 in the apical loop,
were essential for co-immunoprecipitation of full-length
hLARP7 with a 7SK RNA construct comprising SL1 and
SL4 (nucleotides 1–115 linked to 296–331) in vivo (69). Recent chemical footprinting studies of individual hLARP7
domains showed that the La module bound the lower half
of SL4 including the UUU-3 OH and the CTD bound the
upper half of SL4, consistent with the small-angle X-ray
scattering (SAXS) envelope of the hLARP7 CTD bound
to a 7SK SL4 construct (66). A single G312C substitution
resulted in a loss of affinity for the C-terminal RRM2 observed by EMSA (66). To identify the important SL4 nucleotides for high-affinity binding to the hLARP7 xRRM,
the binding affinity of different SL4 RNA constructs to
RRM2-561 was measured by ITC (Figure 5A and Table
3). Substitution of the 5 -AUGUG-3 apical loop with the
canonical UUCG tetraloop completely abolished binding
to hLARP7 xRRM2 (Figure 5C). Substitution of apical
loop residue G312C, which has been shown in vivo and
in vitro to abrogate hLARP7 binding, reduced the binding
affinity 5-fold (KD = 607 ± 130 nM) (Figure 5C and Table 3). These results indicate that the apical loop in general
and G312 specifically are required for specific binding to the
hLARP7 xRRM2. A construct of SL4 with only the upper
stem and apical loop (SL4(306-318)) binds RRM2-561 with
a KD of 35 ± 13 nM (Figure 5B and Table 3), a ∼4-fold increase in binding affinity compared to 129 ± 29 nM for SL4.
Deletion of the C320, U321 bulge from SL4 (CU) also re-

sulted in an increase in binding affinity (∼6-fold, 19 ± 2 nM)
(Figure 5B). These results provide further evidence that the
CU bulge is not part of the xRRM binding site, and in fact
decreases binding affinity. C320 in the CU bulge was proposed to form a base triple with the G303-C323 base pair
in the lower stem in the free SL4 (23); whether this triple
forms in the free RNA or when hLARP7 binds under the
ITC buffer conditions, and if so, interferes with binding of
helix ␣3x remains to be determined. Together, these data
define the binding site for hLARP7 xRRM as the upper
stem-loop of SL4 and indicate that the CU bulge does not
contribute to specific binding.
To further investigate the binding site of hLARP7
xRRM2 on the 7SK SL4 RNA, we mapped chemical shift
changes in 1D and 2D spectra of a SL4(302-324), consisting of residues 302–324 with a terminal G-C base pair, on
addition of RRM2-556 to form a RRM2-556:SL4 complex
that saturated at a 1:1.2 ratio. CSPs were observed for imino
resonances for the top four base pairs (C306-G318, U307A317, G308-C316, C309-G315) (Figure 6A). Comparison
of 2D H5-H6 TOCSY spectra shows CSPs to pyrimidines
in the upper helix (residues C306, U307, C309, C316) and
apical loop (residues U311 and U313) in agreement with
ITC data above (Figure 6B and Table 3). Also in agreement
with this data, when unlabeled RRM2-582 was added to
uniformly 13 C,15 N-labeled SL4 large CSPs (>0.1 ppm) were
observed for all apical loop residues as well as base paired
nucleotides U307, G308, C309 and G318, and modest CSPs
(0.07–0.1 ppm) were observed for C306, G315, C316 and
A317 in the 1 H–13 C C6H6/C8H8/C2H2 HSQC spectrum
(Supplementary Figure S6). Interestingly, small CSPs (0.030.07 ppm) were also observed for the CU bulge and flanking base pairs (C304, G305, U319, C320, U321 and G322).
RRM2-582 contains an additional ␣4 helix (residues 559–
571) that contains several basic residues and may contribute
to the small observed difference in binding affinity (Table 2)
between RRM2-582 and RRM2-561. Together, the NMR
and ITC data show that a combination of base paired and
single-stranded residues are involved in SL4 binding to the
hLARP7 xRRM2 (Figure 6C).

Figure 5. The upper stem and apical loop of SL4 RNA are required for high-affinity binding to the hLARP7 xRRM2. (A) (left) SL4 construct with
substitutions marked with arrows, (right) ITC plot of SL4 binding to RRM2-561. (B) ITC plots of (left) CU and (right) Stem1 constructs binding to
RRM2-561 show that the lower 7SK stem is not required for binding to hLARP7 xRRM. (C) ITC plots of (left) G312C and (right) UUCG substitutions
to the apical loop show that the apical loop, and G312 in particular, are required for high affinity binding to RRM2-561.
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Table 3. 7SK SL4 determinants for binding to hLARP7 xRRM2
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Figure 6. hLARP7 xRRM2 interacts with both the upper stem and loop
residues of SL4. (A) 1D imino proton and (B) 2D H5-H6 TOCSY spectra of SL4 RNA (residues 302–325) free (black) and bound to hLARP7
RRM2-556 (blue). (C) CSPs from (A) and (B) with CSPs from addition of
RRM2-582 to SL4 (Supplementary Data) over 0.07 ppm are combined to
map the xRRM binding surface.

DISCUSSION
Comparison of RNA recognition by hLARP7 and p65 xRRM
Based on sequence homology, we previously proposed that
the xRRM identified in the telomerase LARP7 protein p65
was common to genuine La and LARP7 family proteins
(52,53). Here we provide a second example in hLARP7,
confirming our hypothesis at least for LARP7 family proteins. Canonical RRMs typically bind single-stranded nucleotides and there are few examples of RRMs that bind
double stranded RNA (68). The xRRM is a rare example
of an RRM that recognizes both single and double stranded
RNA residues. Although the hLARP7 CTD was shown in
vivo to be an important specificity factor for 7SK recognition, it was unclear how it achieved this function (43). Here
we show that binding of the xRRM to the upper stem and
loop of 7SK SL4 confers the specificity of hLARP7 for the
7SK transcript vs. other RNAPIII transcripts that have a
UUU-3 OH.
Although p65 and hLARP7 xRRM recognize both unpaired and base paired nucleotides, they interact with different RNA motifs. The p65 xRRM binds an internal twonucleotide bulge and G-C base pairs on either side of the
bulge, whereas the hLARP7 xRRM binds an apical loop
and adjacent base pairs in the stem (Figure 7A and B).
Co-immunoprecipitation studies showed that apical loop
residues G312 and U313 are essential for hLARP7 recognition, while other apical loop residues could be substituted
with little effect on hLARP7 binding, and that the upper
stem structure but not sequence is required (69). The chemical shift mapping experiments reported here show that both
the apical loop and base paired residues at the top of SL4
are involved in xRRM recognition (Figure 6). Consistent
with these data, our ITC studies also show that the apical
loop is required for xRRM binding, and a single G312C
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substitution significantly reduces binding affinity (Table 3).
In contrast, the C320, U321 bulge does not contribute to
specific binding of the hLARP7 xRRM.
The structure of the p65 xRRM2:S4 complex revealed
that a proposed RNP3 sequence [(F/Y/W)-X-(D/Q/E/N)]
on the ␤2 strand and R465 in the ␤3 strand are important for recognition of unpaired nucleotides (52). hLARP7
xRRM2 has an RNP3 sequence nearly identical to p65
xRRM (Y483-V484-D485 and Y407-C408-D409, respectively) and shares a conserved arginine residue on ␤3 (R496)
(Figures 1D and 7C and D). In the X-ray crystal structures of free and RNA-bound p65 xRRM, RNP3 residue
Y407 rotates 93◦ about the C-C␣-C␤-C␥ dihedral bond on
binding RNA (Figure 7E and F). This rotation stacks Y407
onto bulged nucleotide G121 and was proposed to act as
a locking mechanism to stabilize the xRRM-RNA complex
(52). Interestingly, in the solution NMR structure of the free
hLARP7 xRRM the analogous residue, Y483, is already in
the ‘bound’ position (Figure 7D) for all 20 lowest energy
structures, suggesting it may be poised for recognition of
an unpaired nucleotide, which is likely G312, the conserved
apical loop residue required for high affinity binding of the
hLARP7 xRRM to SL4. The other p65 RNP3 residue that
interacts with RNA, D409, hydrogen bonds to the WatsonCrick face of G121 while the conserved arginine in ␤3 hydrogen bonds to the Hoogsteen face of G121. In hLARP7,
the equivalent residues D485 and R496 have weighted average CSPs of 0.53 ppm and 0.23 ppm, respectively, suggesting these residues are involved in RNA recognition.
The helix ␣3–␣3x is critical for high affinity binding to
target RNA for both p65 and hLARP7. For p65, no binding was observed when ␣3x was deleted (52). For hLARP7,
deletion of helix ␣3x residues reduced the binding affinity
by an order of magnitude (Table 2). p65 contains several
positively charged amino acids in helix ␣3-␣3x that make
contacts with the RNA phosphate backbone. For example,
helix ␣3 residues K517 and K518 stack on bulged residue
G121 and hydrogen bond to its phosphate moiety, respectively. In hLARP7, equivalent residues are R540 and Q541,
both of which have sidechain amide groups capable of hydrogen bonding to the RNA phosphate backbone, and have
modest CSPs of 0.32 ppm and 0.22 ppm indicating they interact with SL4. In p65, helix ␣3x residues R522, K528,
and K529 interact with the phosphate moieties of bulge
nucleotide G121, base paired nucleotide G146, and base
paired nucleotide G147, respectively. In hLARP7 the equivalent residue to R522 is N545, which still has a sidechain
amide group that can hydrogen bond to the RNA backbone
and has a large CSP, which may also reflect conformational
changes occurring at the ␣3-␣3x boundary. In hLARP7 the
equivalent residues to p65 K528 and K529 are E549 and
K550, respectively. Both E549 and K550 have small back-
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Figure 7. Comparison of RNA binding mode of hLARP7 and p65 xRRM.
(A) 7SK SL4 sequence with nucleotides undergoing CSPs shown in blue
(left) and schematic of hLARP7 xRRM2 binding to SL4 (right). (B)
Tetrahymena telomerase RNA (TER) partial SL4 sequence with nucleotides interacting with p65 xRRM2 shown in blue (left) and schematic
of p65 xRRM2 recognition of TER S4 (right). (C) hLARP7 xRRM2 solution NMR structure with black box denoting RNA binding site. (D)
hLARP7 xRRM2 solution NMR structure with residues D485, R496,
Y532, and W533 shown in stick format, with Y483 shown as a thicker
stick in blue with hydroxyl moiety shown in cyan. (E and F) X-ray crystal structure of p65 xRRM2 (4EYT) (E) and bound to TER S4 (4ERD)
(F). Residues D409, R465, Y510 and W511 are shown in stick format and
Y407 as thicker stick in blue with hydroxyl radical shown in light blue.

bone amide CSPs. In p65, K528 and K529 interact with the
base paired residues on either side of the GA bulge; since
hLARP7 xRRM binds an apical loop, the mechanism for
base paired RNA recognition may differ between p65 and
hLARP7. In p65, aromatic residues F521, F524 and F525
in ␣3x insert between the base pairs on either side of the
GA bulge to induce a ∼105◦ bend in the RNA. Strikingly,
in hLARP7 equivalent residues are hydrophobic or charged
(L544, P547, R548). These differences may reflect the fact
that hLARP7 ␣3x binds at the top of a hairpin rather than
between base pairs on either side of a bulge. The different
modes of RNA recognition between p65 and hLARP7 xRRMs likely gave rise to differences in residues at the ␣3xRNA interface.

Hundreds of RRM structures have been solved, many of
which have atypical features (67,68). Some classes of atypical RRMs lack RNP1 and/or RNP2, but still bind RNA
via loops, e.g. quasiRRMs (qRRMs) (70–72), or helices,
e.g. pseudoRRMs (73) and occluded RRMs (oRRMs) (74).
Some atypical RRMs have an ␣-helix on the ␤-sheet, but
this helix is not used for RNA binding: it either binds protein (75,76) and the RRM is not involved in RNA recognition (77–80), or moves out of the way for RNA binding
(81,82). Although other atypical RRMs contain some unusual features in common with the xRRM, the combination of helix ␣3-␣3x and conserved RNP3 sequence that together form a unique RNA–protein binding interface sets
the xRRM apart.
The hLARP7 xRRM2 (RRM2-561) structure is highly
similar to the solution NMR structures of the p65 xRRM2
(2LSL) (52) and atypical human genuine La protein hLa
RRM2 (1OWX) (83) (Figure 8). p65 contains an unusually
long ␤2-␤3 loop (45 aa) while hLARP7 RRM2 contains a
3 aa ␤2-␤3 loop. The long ␤2-␤3 loop in p65 was shown to
be dispensable for RNA binding and telomerase RNP assembly. Likewise, the hLARP7 xRRM2 ␤2-␤3 loop is not
involved in RNA recognition. p65 also contains an additional ␤4 strand, which has been observed in other RRMs,
including hLa (67). Instead of a ␤4 strand, the hLARP7
xRRM2 has an extended ␣2 helix. Helix ␣3 in both p65
and hLARP7 xRRM2 are similarly positioned on the ␤sheet, although hLARP7 helix ␣3 is one turn longer. The
composition of the ␣3:␤-sheet interface is highly conserved,
particularly at the ␤4-␣3 turn and beginning of helix ␣3
(Figure 1D). For example, hLARP7 hydrophobic residues
I456 and L524 are conserved in p65 (L380 and I502, respectively) with helix ␣3 beginning with aspartic acid for both
proteins. Several residues are identical (E529, Y532, W533,
I536 in hLARP7); these residues all face the ␤-sheet and
appear to stabilize helix ␣3 on the ␤-sheet (Figure 8). In
hLARP7, Y532 stacks upon H494 in ␤3; in p65, analogous
residue Y510 stacks on M462 in an aryl-sulfur interaction
(Figure 8). Overall, the xRRM appears to have a conserved
hydrophobic interface between ␣3 and the ␤-sheet.
Genuine La protein performs a broad range of essential cellular functions both in the nucleus and cytoplasm
(44,84). In higher eukaryotes, La contains a C-terminal
RRM2 that recognizes and is proposed to act as a chaperone for several RNA targets, e.g. pre-tRNA (85,86), the
IRES domain IV of the HCV RNA virus (87), and stemloops of precursor microRNA (88). However, in contrast to
hLARP7 and p65, in which the xRRM binds with nanomolar binding affinity even in the absence of the La module,
the isolated hLa RRM2 has not been shown to stably bind
RNA but rather appears to enhance the binding affinity
when in tandem with the La module, hinting at weak and/or
allosteric binding (87,88). While the hLa RRM2 has xRRM
features it has not yet been confirmed to be an xRRM.
Overall hLa RRM2 has a very similar structure to p65 and
hLARP7 xRRM2. There are small differences in the positions and length of helix ␣1 and ␣2. The ␤4–␣3 turn and
RNP3 sequence are conserved between hLARP7 and p65
xRRM2 and hLa RRM2 (Figure 8). Although helix ␣3 lies
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Figure 8. Comparison of structures and interaction of ␣3 with the ␤-sheet
of RRM2 of hLARP7, p65, and hLa. Solution NMR structures of (top)
side and (bottom) front views of (A) hLARP7 xRRM2, (B) p65 xRRM2
(PDB: 2LSL) and (C) hLa RRM2 (PDB: 1OWX). Side chains at the ␣3-␤sheet interface are shown colored by type (aromatic, yellow; hydrophobic,
green; charged, purple).

across the ␤-sheet in all the structures, in hLARP7 and to a
lesser extent p65 xRRM2 the C-terminal end of helix ␣3 tilts
away from the ␤-sheet surface, whereas in the hLa RRM2
helix ␣3 lies at a uniform distance across the ␤-sheet and is
closer to the ␤-sheet. In hLa, helix ␣3 is stabilized on the ␤sheet predominantly by hydrophobic interactions between
leucines and isoleucines, compared to p65 and hLARP7
which have similar interfaces to hLa RRM2 at the ␤4-␣3
turn but have more aromatic and charged residues at the interface between ␤3-␤2 and the C-terminal end of helix ␣3.
The putative RNA binding surface of hLa RRM2 has
some differences compared to known xRRMs p65 and
hLARP7. Although it has the RNP3 sequence on ␤2, it has
a leucine on ␤3 instead of an arginine. In p65, R465 (R496 in
LARP7) hydrogen bonds to unpaired nucleotides and is important for high affinity binding to RNA (52). In addition,
hLa RRM2 has relatively few charged or aromatic residues
in helix ␣3 that face the putative RNA binding site compared to hLARP7 and p65 (Figure 8). Residues 316–332
of hLa RRM2, comprising helix ␣3 and the putative helix
␣3x, function as a nuclear retention element that is required
for binding and processing pre-tRNA (83,89). The putative
hLa helix ␣3x (residues 327–332) is disordered in the solution NMR structure (83) and is extremely basic (Figure
1D), although it remains to be shown whether it forms helix ␣3x on binding specific RNA targets. In contrast to p65
and hLARP7, hLa RRM2 has multiple binding partners
and may have evolved an xRRM2 to have weak affinity to
RNA so that it can be released.
hLARP7 xRRM2 is required for specific recognition of 7SK
SL4 RNA
A small fraction of 7SK RNA is found bound to hLa, and
it is thought that hLa binds first to 7SK RNA to protect the
UUU-3 OH end and is replaced with hLARP7 (44,90). Previously it was shown that deletion of the hLARP7 CTD (aa

408–582) caused it to lose specificity to 7SK RNA in vivo
(43), indicating that the CTD contained a required specificity factor for 7SK RNA recognition. Here we show that
the CTD contains an xRRM that binds to the SL4 apical
loop and upper stem with high affinity. We propose the following model for hLARP7 recognition of 7SK RNA. Genuine hLa binds the nascent 7SK RNA at the UUU-3 OH
end as it exits RNAPIII. The hLARP7 xRRM2 recognizes
the 7SK SL4 apical loop and binds with high affinity. hLa is
either actively or passively displaced at the UUU-3 OH end
and replaced with the hLARP7 La module, resulting in the
stable association of hLARP7 with 7SK RNA.
hLARP7 appears to enhance the association of MePCE,
HEXIM, and P-TEFb to assemble the ‘active’ 7SK snRNP
in vitro and in vivo (28,43). In vitro co-immunoprecipitation
experiments showed that an hLARP7 CTD construct
(starting at residue 375) pulled down P-TEFb subunit
CDK9 as efficiently as full-length hLARP7, suggesting
the hLARP7 CTD directly interacts with CDK9 (42). An
hLARP7 construct (1–561) lacking the last 21 aa expressed
in vivo was unable to co-immunoprecipitate P-TEFb and
pulled down only a fraction of 7SK RNA in separate coimmunoprecipitation experiments (43). However, our studies show that in vitro the C-terminal 21 residues are beyond
the boundary of the xRRM and are not required for 7SK
SL4 recognition. Therefore, the hLARP7 C-terminus may
be important for interaction with P-TEFb subunit CDK9
or for protein stability in vivo.
Although 7SK SL4 has been proposed to interact with
the HIV TAT protein and the P-TEFb subunit Cyclin T1 at
the SL4 apical loop (23,91), it has been conclusively shown
that TAT binds to SL1 (92,93). Nevertheless, 7SK SL4 has
similar structural features as the HIV transactivation response (TAR) element and so it is useful to discuss here. The
X-ray crystal structure of the EIAV TAR:Cyclin T1:TAT
ternary complex shows that Cyclin T1 interacts with two
extruded EIAV apical loop nucleotides and a TAT helix interacts with the TAR major groove (94). Our studies show
that the hLARP7 xRRM2 binds at the SL4 apical loop and
upper stem, and we propose that the helix ␣3x inserts into
the major groove (Figure 7A), occluding TAT binding and
potentially Cyclin T1 binding to 7SK SL4.
hLa and LARPs frequently act as chaperones, facilitating RNA re-folding or protein recruitment onto RNA, in
addition to protecting RNAP transcripts from degradation via binding of the La module to UUU-3 OH (44,45).
For example, the p65 xRRM2 induces a large conformational change in Tetrahymena telomerase RNA that enhances binding of telomerase reverse transcriptase (TERT)
by positioning Tetrahymena telomerase S4 RNA for interaction with TERT (52,95). It is possible that the LARP7
xRRM:SL4 complex positions the SL4 apical loop for favorable contacts with P-TEFb (Cyclin T1), similarly to how
TAT enhances Cyclin T1 binding to TAR and p65 xRRM
enhances telomerase assembly. Future studies on the structure of the LARP7 xRRM2 bound to 7SK SL4 RNA will
further elucidate the protein-RNA interactions that enable
specificity and provide further insights into the functional
role of LARP7 xRRM2 in P-TEFb assembly onto the 7SK
snRNP. The studies presented here show that the xRRM is
not unique to p65 but rather is conserved in the LARP7 pro-
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tein family and provide insight into how the hLARP7 CTD
confers specificity toward 7SK RNA over other RNAPIII
transcripts.
ACCESSION NUMBER
Coordinates for the 20 lowest energy structures of hLARP7
xRRM (residues 445–561) have been deposited in the Protein Data Base under accession code 5KNW and chemical
shifts and NMR restraints used for structure calculations
have been deposited in the BioMagResBank under accession code 30126.
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